Cargando…

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lefort, S, Thuleau, A, Kieffer, Y, Sirven, P, Bieche, I, Marangoni, E, Vincent-Salomon, A, Mechta-Grigoriou, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340801/ https://www.ncbi.nlm.nih.gov/pubmed/27669438 http://dx.doi.org/10.1038/onc.2016.284

Ejemplares similares

A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer
por: Faucheux, L., et al.
Publicado: (2019)

MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas
por: Gruosso, Tina, et al.
Publicado: (2015)

Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer
por: Mieulet, Virginie, et al.
Publicado: (2021)

miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
por: Givel, Anne-Marie, et al.
Publicado: (2018)

Definition of a novel breast tumor-specific classifier based on secretome analysis
por: Sirven, Philémon, et al.
Publicado: (2022)

CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer
por: Magagna, Ilaria, et al.
Publicado: (2021)

EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma
por: Shen, Wei-Wei, et al.
Publicado: (2020)

Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
por: Kieffer, Yann, et al.
Publicado: (2020)

Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients
por: Gruosso, Tina, et al.
Publicado: (2016)

A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer
por: Bonneau, Claire, et al.
Publicado: (2020)

Tumor Cells and Cancer-Associated Fibroblasts: An Updated Metabolic Perspective
por: Gentric, Géraldine, et al.
Publicado: (2021)

Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer
por: Mhaidly, Rana, et al.
Publicado: (2021)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
por: Goldstein, Lori J., et al.
Publicado: (2020)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells
por: Yang, Meng, et al.
Publicado: (2019)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
por: Goldstein, Lori J., et al.
Publicado: (2020)

Heterogeneity in Cancer Metabolism: New Concepts in an Old Field
por: Gentric, Géraldine, et al.
Publicado: (2017)

PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer
por: Noureddine, Lara Malik, et al.
Publicado: (2023)

Control of cancer-associated fibroblast function by oxidative stress: A new piece in the puzzle
por: Scholer-Dahirel, Alix, et al.
Publicado: (2013)

miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
por: Ninio-Many, Lihi, et al.
Publicado: (2020)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple-negative breast cancer metastasis via the inhibition of CXCR4 expression
por: Takeda, Tomoya, et al.
Publicado: (2023)

Dissection of intercellular communication using the transcriptome-based framework ICELLNET
por: Noël, Floriane, et al.
Publicado: (2021)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Ghallab, Alaa M., et al.
Publicado: (2022)

The CXCR4-Dependent LASP1-Ago2 Interaction in Triple-Negative Breast Cancer
por: Tilley, Augustus M. C., et al.
Publicado: (2020)

Triple-Negative Breast Cancer Cells Recruit Neutrophils by Secreting TGF-β and CXCR2 Ligands
por: SenGupta, Shuvasree, et al.
Publicado: (2021)

Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts
por: de Plater, Ludmilla, et al.
Publicado: (2014)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine
por: Fazekas, Judit, et al.
Publicado: (2016)

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients
por: Alwan, Nada A. S., et al.
Publicado: (2019)

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
por: Dakroub, Rayan, et al.
Publicado: (2023)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer
por: Wang, Yuyi, et al.
Publicado: (2018)

Role of the CXCR4-LASP1 Axis in the Stabilization of Snail1 in Triple-Negative Breast Cancer
por: Subramaniyan, Boopathi, et al.
Publicado: (2020)

Saikosaponin A Inhibits Triple-Negative Breast Cancer Growth and Metastasis Through Downregulation of CXCR4
por: Wang, Ying, et al.
Publicado: (2020)

Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC)
por: Chuan, Tian, et al.
Publicado: (2020)

CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0vfn9qmu73vuc0e0ake0lr2e07